Long-acting β-agonists (LABAs) should never be used to treat asthma without a corticosteroid or other asthma controller medication, according to new recommendations from the US Food and Drug Administration (FDA) aimed at reducing rare but serious adverse events associated with these drugs. Even use of combination products should be limited to instances in which it is absolutely necessary, the agency advised.
Kuehn BM. FDA Offers Advice to Reduce Risks of Long-Acting β-Agonists in Asthma Care. JAMA. 2010;303(14):1353-1354. doi:10.1001/jama.2010.357